Anti-C5a receptor antibodies
The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
1. An isolated antibody that specifically binds C5aR
comprising a CDRH1 having the sequence of SEQ ID NO: 9,
a CDRH2 having the sequence of SEQ ID NO: 10,
a CDRH3 having the sequence of SEQ ID NO: 11, a CDRL1 having the sequence of SEQ ID NO: 13, a CDRL2 having the sequence of SEQ ID NO: 14, and a CDRL3 having the sequence of SEQ ID NO: 15.
2. The antibody of claim 1 , wherein the antibody is a human antibody.
3. The antibody of claim 1 wherein the antibody is a humanized antibody.
4. The antibody of claim 1 wherein the antibody specifically binds the second extracellular loop of C5aR.
5. The antibody of claim 1 wherein the antibody comprises an Fc region comprising IgG1 (SEQ ID NO: 33) having amino acid substitutions L234A, L235E, G237A, A330S and P331S.
6. The antibody of claim 1 comprising a V H having the sequence of SEQ ID NO: 39.
7. The antibody of claim 1 comprising a V L having the sequence of SEQ ID NO: 40.
8. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.